Thanks abdm, It has been great to be away but I enjoy to be back as well !
Today's trading action had to put a smile on everybody's face who followed this action for some time. How quickly those cappers were at work when we saw the slightest buying action in which I, same as Smilez, took part in.
You stated in your post that the FMCG now tests our technology and applies it to their pipeline for 4 years, so does GSK. The usual testing regime cycle lasts for about 5 years so we are heading for conclusion in this year on many fronts, not just one.
As much as it might appear to some holders that these testing cycles never end, they actually do and quite rapidly so without much warning ahead of the event. For much discussed reasons, the pharma industry is ready for innovations and all the technologies which are at a late stage within their testing regimes as OBJ are the ones preferably seeing action this year in terms of contracts, licence deals and upfront payments.
An article which in general strokes sums up the outlook on transdermal deliveries particularly mentions iontophoresis, once again.
Two of the better-known technologies that can help achieve significant skin permeation enhancement are iontophoresis and phonophoresis (sonophoresis). Iontophoresis involves passing a direct electrical current between two electrodes on the skin surface. Phonophoresis uses ultrasonic frequencies to help transfer high molecular weight drugs through the skin.
While he acknowledges that iontophoresis is at the forefront of innovative patch deliveries, he claims that micro needles are representing possibly the more likely version to be successful in future.
This article about a dissolving microneedle patch though illustrates excactly the problems with that technology.
The dissolving microneedle patch was well tolerated, causing only slight, transient erythema. This study suggests that a dissolving microneedle patch can deliver hGH and other biopharmaceuticals in a manner suitable for self-administration without sharp biohazardous waste.
First it states that microneedle patches create biohazardous waste which should be avoided. Secondly, slight erythema ( red skin irritation ) still occurs. Microneedle patches, even if dissolving, could never be, in my opinion, as uninvasive as our magnetic system which does leave no trace whatsoever.
The costs for a microneedle patch would also always be higher than our magnetic strip due to material and amount of microneedles necessary to guarantee efficient drug flow.
The market action since early December triggered my suspicion of news to be expected which did not eventuate so close to xmas and new year, which probably should have been anticipated. As much as OBJ management would like to inform us, they need to confirm and follow the time tables and schedules of the market giants they share agreements with. Those companies do have slow moving executive wheels and nothing happens after early December. Therefore, our expected updates from early December would be actually due soon within early Jan.
I expect something material around mid Jan, am also curious about peer company development in the Bio Business conference in the UK from the 19th to the 20th.
OBJ Price at posting:
2.3¢ Sentiment: Buy Disclosure: Held
(20min delay)